ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
Senores Pharmaceuticals held its 9th Annual General Meeting on September 25, 2026. Shareholders approved financial statements, director appointments, and the new Employee Stock Option Scheme 2026.
Senores Pharmaceuticals informed exchanges there is no undisclosed or price-sensitive information behind the volume spike. The company affirmed compliance with SEBI LODR disclosure obligations.
Senores Pharmaceuticals Ltd submitted its shareholding pattern for the quarter ended 31 March 2026, in compliance with SEBI regulation 31(1)(b).
Senores Pharma's subsidiary Apnar Pharma completed a USFDA inspection at its Vadodara facility with no GMP observations. Only one minor procedural finding was noted.
Senores Pharmaceuticals issued a corrigendum to its FY 2025-26 Annual Report to rectify typographical errors in the narrative and Director's Report sections. The original report remains valid.
Senores Pharmaceuticals Ltd submitted its Annual Report for FY 2025-26 and notice for its 9th Annual General Meeting scheduled for September 25, 2026.
Senores Pharmaceuticals delivered strong Q1 FY27 growth, doubling approved ANDAs to 58. Management is pivoting strategy toward profitability in domestic branded generics while scaling US operations via new specialized subsidiaries.
Senores Pharmaceuticals delivered robust Q1FY27 performance with revenue growing 36% and EBITDA 87% YoY, driven by strong growth in regulated markets and margin expansion of ~800 bps.
Senores Pharmaceuticals Ltd reported revenue from operations of ₹180.2 Cr (+35.9% YoY) and net profit of ₹30.4 Cr (+43.4% YoY) for Q1 FY27.